On November 30, 2021 CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, reported a presentation on Centurion BioPharma Corporation’s ("Centurion BioPharma") plans for a world-class cancer center in Las Vegas, Nevada (Press release, Cytran, NOV 30, 2021, View Source [SID1234596286]). Centurion BioPharma is a private wholly-owned subsidiary that focuses on advancing the Company’s proprietary, albumin binding ultra-high potency LADR (Linker-Activated Drug Release) oncology drug candidates and ACDx diagnostic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, which can be found here, highlights how the planned center would:

Be incorporated as a 501(C)3 not for profit organization and funded with $100 million or more in tax deductible gifts and grants raised from outside organizations, including foundations, philanthropists and other individual donors.
Centurion BioPharma would receive a percentage of the funds raised from the cancer center for the completion of its Investigational New Drug (IND)-enabling studies and clinical trials.
Establish a world-class oncology team dedicated to delivering compassionate care and truly innovative cancer treatments.
Implement approved therapies that have been proven to possess clinical benefit as well as be a scientific hub for additional research and new clinical trials for the next generation of cancer-fighting drugs.
Help establish Las Vegas, Nevada as a future center for medical tourism, allowing residents of Nevada and non-residents to receive best-in-class treatment.
Move Centurion BioPharma’s headquarters to Las Vegas, Nevada while it maintains a satellite office in Los Angeles, California.
Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx and Executive Chairman of Centurion BioPharma, commented:

"At CytRx and Centurion BioPharma, we believe establishing a best-in-class healthcare center in the city of Las Vegas can provide advanced cancer care and research for patients, establish Las Vegas as an important hub for further groundbreaking treatments and assist in the development of Centurion BioPharma’s LADR technology. Over the last three years, Centurion BioPharma has made critical strides in the development and diagnostics of its therapies. A combination immunotherapy including aldoxorubicin, which was developed by the Centurion BioPharma research team, was recently proven successful in a Phase 2 trial for advanced metastatic pancreatic cancer. We believe that establishing a major cancer center in Las Vegas – which we aim to complete with philanthropic support – will enable Centurion BioPharma to continue its important scientific research and pursue transformational treatment programs."

On November 30, 2021 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in investor conferences in December 2021 (Press release, Ideaya Biosciences, NOV 30, 2021, View Source [SID1234596303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI HealthConX Conference
Thursday, December 2, 2021 at 10:30 am ET

Fireside Chat with Yujiro Hata, Chief Executive Officer, hosted by Josh Schimmer, M.D., M.B.A, Fundamental Research Analyst
A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of available webcasts will be accessible for 30 days following the live event.

On November 30, 2021 THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, reported that it has received yesterday a letter from BIOSYNEX informing it of its acquisition of a stake in its capital and the crossing of statutory thresholds, in accordance with article 12.3 of THERADIAG’s articles of association (Press release, Theradiag, NOV 30, 2021, View Source [SID1234596230]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following acquisitions on the market and its participation in the Rights Issue, BIOSYNEX held 2,468,932 shares, i.e. 18.82% of THERADIAG’s share capital and 18.89% of its voting rights, as at 29 November 2021 at 8:00 a.m.

On November 30, 2021 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET – 1:30pm EST (Press release, Delcath Systems, NOV 30, 2021, View Source [SID1234596248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will focus on the company’s US product candidate, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), a percutaneous hepatic perfusion (PHP) system. In the United States HEPZATO is an investigational drug/device combination product. In Europe, the product is a stand-alone medical device approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

A distinguished panel of physicians will discuss their experience with HEPZATO in the FOCUS trial, commercial experience with CHEMOSAT and the unmet need in the treatment of liver metastases. The participating physicians will present on the following topics:

Current unmet need and treatment options for liver metastases
The longest single institution experience with PHP – The University Hospital Southampton experience
PHP quality of life and combination with immuno-oncologic therapy – The Leiden University experience
Current unmet needs in ocular melanoma
Focus Trial – efficacy and safety results
Future clinical development plans
In addition to the Delcath management team, planned speakers and panelists will include:

John Bridgewater, MRCP, PhD, FRCP
Professor and Consultant Medical Oncologist, UCL Cancer Institute, University College London, London, UK

Mark Burgmans, MD, PhD
Head of Interventional Radiology, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

Aslam Ejaz MD, MPH
Assistant Professor of Surgery, The Ohio State University, Columbus, OH

Francesco Pier Ferrucci, MD
Director, Tumor Biotherapy Unit, Istituto Europeo di Oncologia, Milan, Italy

Evan S. Glazer, MD, PhD, FACS
Assistant Professor of Surgery, College of Medicine and Principal Investigator, Center for Cancer Research, The University of Tennessee Health Science Center, Memphis, TN

Sachin Modi, BSc (Hons), MBBS, FRCR, FRCR (IR)
Consultant Interventional Radiologist, Department of Interventional Radiology, University Hospital Southampton, Southampton, UK

Siddharth A. Padia, MD
HS Clinical Professor, Division of Interventional Radiology, David Geffen School of Medicine, University of California, Los Angeles, CA

Sapna Patel, MD
Associate Professor, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX

Sunil A. Reddy, MD
Clinical Assistant Professor, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California

Brian Stedman, BSc, MBBS, FRCS, FRCR
Consultant Interventional Oncologist, Department of Interventional Radiology, University Hospital Southampton, Southampton, UK

Juan Valle, MD
Professor and Consultant Medical Oncologist, The Christie NHS Foundation Trust, Manchester, UK

Jonathan Zager, MD, FACS (Global Lead Investigator)
Chief Academic Officer, Director of Regional Therapies, and Senior Member, Departments of Cutaneous Oncology and Sarcoma, Moffitt Cancer Center; Chair, Department of Oncological Sciences and Professor of Surgery, USF, Morsani School of Medicine, Tampa, FL

Event Details:
Event: Delcath Systems Virtual Investor Update Meeting
Date: Thursday, December 2, 2021
Time: 10:00am – 1:30 p.m. EST

On November 30, 2021 Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that it will report financial results for the second quarter of fiscal year 2022 on December 7, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, NOV 30, 2021, View Source [SID1234596267]). Members of Avid’s senior management will discuss financial results for the first quarter and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.